Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Investigate whether infusion of the GLP-1RA, exenatide during cardiopulmonary bypass and weaning thereof, can mitigate the decline in diffusing capacity and ventilatory performance 3 months postoperative, compared to placebo.

Why It Was Studied

Postoperative pulmonary decline is an established complication of open-heart surgery extending beyond the immediate postoperative phase.

Inflammation-mediated lung damage and ischaemia-reperfusion injury secondary to extracorporeal circulation is a proposed pathophysiological driver.

Who Took Part

The study group was 878 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In this predefined explorative substudy of the randomised, clinical GLORIOUS trial, 878 adult patients undergoing non-emergent coronary artery bypass grafting (CABG) and/or surgical aortic valve replacement (SAVR) were randomised to a continuous infusion of the GLP-1RA, exenatide or placebo during cardiopulmonary bypass, extending into the early postoperative period.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

Diffusing capacity of the lung for carbon monoxide (DLCO) and ventilatory performance (FEV1/FVC) were measured preoperatively and 3 months postoperatively.

What Was Measured

Inflammation-mediated lung damage and ischaemia-reperfusion injury secondary to extracorporeal circulation is a proposed pathophysiological driver.

The subject headings attached to it are Exenatide, Postoperative Complications, Cardiopulmonary Bypass, Glucagon-Like Peptide-1 Receptor Agonists, Coronary Artery Bypass, Venoms and Cardiac Surgical Procedures.

The authors tagged it with the keywords DLCO, FEV1/FVC, glucagon‐like peptide‐1 receptor agonist, open‐heart surgery, postoperative pulmonary decline and pulmonary protection.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 878 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Acta anaesthesiologica Scandinavica), a journal based in England.

More context: the Exenatide compound page, all human trials.